Global Interferon Gamma Release Assay (IGRA) Market Outlook: Analyzing Drivers from Latent TB Infection Screening and Competitive Strategies, 2025–2032.
Overview Of QuantiFERON-TB Gold
The global market for the QuantiFERON-TB
Gold (QFT) test—a leading Interferon-Gamma Release Assay (IGRA) used to
diagnose Latent Tuberculosis Infection (LTBI)—is experiencing robust growth,
driven primarily by the global shift away from the less specific Tuberculin
Skin Test (TST). The QFT test, notably the latest version, QuantiFERON-TB Gold
Plus (QFT-Plus), offers superior specificity by eliminating false-positive
results caused by the BCG vaccine.
This precision makes it a crucial diagnostic
tool in high-income and developed regions with stringent screening mandates,
such as for healthcare workers and immunocompromised patients.
The increasing global burden of TB and
growing awareness campaigns, particularly in developing economies, are further
accelerating the adoption of this modern, blood-based diagnostic solution.
Get a Sample Report QuantiFERON-TB Gold Forecast @ https://www.databridgemarketresearch.com/request-a-sample?dbmr=global-quantiferon-tb-gold-test-market
Market Size, Share, and Forecast
The QuantiFERON-TB Gold Test market was
valued at USD 679.48 million in 2024. The market is projected
to expand significantly, reaching an estimated value of USD 1,239.15
million by 2032. This growth trajectory corresponds to a Compound
Annual Growth Rate (CAGR) of 7.8% during the forecast period.
This strong CAGR is indicative of the rapid
conversion rate from traditional TST methods to IGRAs and the continued
emphasis on early detection and prevention of active tuberculosis, particularly
in vulnerable populations.
The
market share is heavily concentrated around the core product, QFT-Plus, which
dominates the IGRA segment due to its advanced technology and widespread
regulatory approvals.
Segmentation Analysis
The market is segmented based on several key
factors:
1.
Brand: Dominated by the QFT-Plus (QuantiFERON-TB
Gold Plus) brand, which includes proprietary CD8+ T-cell technology for a more
complete immune response assessment.
2.
Test Type
(Broader Latent TB Testing Market):
While the market is increasingly defined by Interferon Gamma Release
Assays (IGRAs), the traditional Tuberculin Skin Test (TST) still holds
significant volume, though IGRAs are the faster-growing segment.
3.
Application: Key application areas include screening for People
Living with HIV (PLHIV) and high-risk groups such as household contacts
of pulmonary TB patients.
4.
End User: The primary end-users are Diagnostic
Laboratories, followed by hospitals/clinics and academic &
research institutions. Diagnostic labs facilitate the high-throughput,
automated testing capabilities required by the QFT platform.
Do you have any specific queries or need
any customized QuantiFERON-TB Gold Submit
your inquiry here @ https://www.databridgemarketresearch.com/inquire-before-buying?dbmr=global-quantiferon-tb-gold-test-market
Key Players
The market landscape for the QuantiFERON-TB
Gold test is largely consolidated, with the manufacturer of the technology
holding a dominant position. Key players in the wider latent TB testing market
include:
- Qiagen (Germany)
- Thermo Fisher Scientific Inc.
(U.S.)
- Abbott (U.S.)
- BD (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Hologic, Inc. (U.S.)
- Meridian Bioscience, Inc. (U.S.)
- QuidelOrtho Corporation (U.S.)
- Bio-Rad Laboratories Inc. (U.S.)
- Laboratory Corporation of America Holdings
(U.S.)
- Aster Clinical Lab LLP (India)
- DiaSorin S.p.A. (Italy)
- Portea Medical (India)
- SSI DIAGNOSTICA (Denmark)
This Long-Tail Semantic Indexing (LSI)
keyword highlights the core clinical application and purpose of the
QuantiFERON-TB Gold test.
Get A Buy Now Report QuantiFERON-TB Gold Forecast @ https://www.databridgemarketresearch.com/checkout/buy/global-quantiferon-tb-gold-test-market/compare-licence
Future Outlook
the QuantiFERON-TB Gold Test market is
expected to solidify its position as the preferred method for LTBI diagnosis in
developed regions. The high CAGR of 7.8% projected through 2032 is underpinned
by continuous technological advancements, such as the QFT-Plus's CD8+ T-cell
capability, and the strategic push by leading manufacturers like QIAGEN into
emerging, high-burden TB countries.
About Us:
Data Bridge is one of the leading market
research and consulting agencies that dominates the market research industry
globally. Our company's aim is to give clients the knowledge they require in
order to function in changing circumstances. In order to give you current,
accurate market data, consumer insights, and opinions so that you can make
decisions with confidence, we employ a variety of techniques, including
surveys, video talks, and focus groups around the world.
For More
Reports:
Passive Electronic Components
Market
Contact :
Data
Bridge Market Research Private Ltd .
3665
Kingsway - Suite 300 Vancouver BC V5R 5W2 Canada
+1 614
591 3140 (US)
Comments
Post a Comment